...
首页> 外文期刊>Journal of the American College of Cardiology >Prognostic utility of neutrophil gelatinase-associated lipocalin in predicting mortality and cardiovascular events in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention
【24h】

Prognostic utility of neutrophil gelatinase-associated lipocalin in predicting mortality and cardiovascular events in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention

机译:中性粒细胞明胶酶相关脂蛋白在预测经原发性经皮冠状动脉介入治疗ST段抬高型心肌梗死患者的死亡率和心血管事件中的预后作用

获取原文
获取原文并翻译 | 示例
           

摘要

Objectives: The aim of this study was to investigate the prognostic role of neutrophil gelatinase-associated lipocalin (NGAL) in a large population of patients with ST-segment elevation myocardial infarction. Background: NGAL is a glycoprotein released by damaged renal tubular cells and is a sensitive maker of both clinical and subclinical acute kidney injury. New data have demonstrated that NGAL is also stored in granules of mature neutrophils, and recent data suggest that NGAL may also be involved in the development of atherosclerosis. NGAL is significantly increased in patients with myocardial infarction compared with patients with stable coronary artery disease and healthy subjects. However, the prognostic value of NGAL has never been studied in patients with myocardial infarction. Methods: We included 584 consecutive ST-segment elevation myocardial infarction patients admitted to the heart center of Gentofte University Hospital, Denmark, and treated with primary percutaneous coronary intervention, from September 2006 to December 2008. Blood samples were drawn immediately before primary percutaneous coronary intervention. Plasma NGAL levels were measured using a time-resolved immunofluorometric assay. The endpoints were all-cause mortality (n = 69) and the combined endpoints (n = 116) of major adverse cardiac events (MACE) defined as cardiovascular mortality and admission due to recurrent myocardial infarction or heart failure. The median follow-up time was 23 months (interquartile range, 20 to 24 months). Results: Patients with high NGAL (>75th percentile) had increased risk of all-cause mortality and MACE compared with patients with low NGAL (log-rank test, p < 0.001). After adjustment for confounding risk factors chosen by backward elimination by Cox regression analysis, high NGAL remained an independent predictor of all-cause mortality and MACE (hazard ratio: 2.00; 95% confidence interval: 1.16 to 3.44; p = 0.01 and hazard ratio: 1.51; 95% confidence interval: 1.00 to 2.30; p = 0.05, respectively). Conclusions: High plasma NGAL independently predicts all-cause mortality and MACE in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention.
机译:目的:本研究的目的是研究嗜中性粒细胞明胶酶相关脂质运载蛋白(NGAL)在大量ST段抬高型心肌梗死患者中的预后作用。背景:NGAL是受损肾小管细胞释放的糖蛋白,是临床和亚临床急性肾损伤的敏感制造者。新数据表明,NGAL也存储在成熟的中性粒细胞颗粒中,最近的数据表明,NGAL也可能参与动脉粥样硬化的发展。与稳定冠心病和健康受试者相比,心肌梗死患者的NGAL显着增加。但是,从未研究过NGAL对心肌梗死患者的预后价值。方法:我们纳入了2006年9月至2008年12月在丹麦Gentofte大学医院心脏中心住院并经原发性经皮冠状动脉介入治疗的584例连续ST段抬高型心肌梗死患者。 。使用时间分辨免疫荧光测定法测量血浆NGAL水平。终点为全因死亡率(n = 69),主要不良心脏事件(MACE)的综合终点(n = 116)定义为心血管疾病的死亡率和因反复发作的心肌梗塞或心力衰竭而入院。中位随访时间为23个月(四分位间距为20到24个月)。结果:与低NGAL的患者相比,高NGAL(> 75%百分数)的患者全因死亡率和MACE的风险增加(对数秩检验,p <0.001)。在通过Cox回归分析通过向后消除选择的混杂风险因素进行调整后,高NGAL仍然是全因死亡率和MACE的独立预测因子(危险比:2.00; 95%置信区间:1.16至3.44; p = 0.01和危险比: 1.51; 95%置信区间:1.00至2.30; p = 0.05)。结论:高血浆NGAL可以独立预测接受原发性经皮冠状动脉介入治疗的ST段抬高型心肌梗死患者的全因死亡率和MACE。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号